MaxCyte Inc Dossier
|
SectorHealth Care IndustryLife Sciences Tools & Services Beta (adjusted)1.32 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $1.09Price as of 1 Oct 2026 Data confidenceNot applicable Market Cap $112.5M Enterprise Value $97.5M Shares Outstanding 107.1M diluted Next Earnings Date11 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary MaxCyte is a leading cell-engineering company whose proprietary Flow Electroporation technology is a critical enabler for next-generation cell therapies. Despite recent macroeconomic headwinds and program rationalization by customers that pressured core revenues, the company's long-term growth remains anchored by its expanding Strategic Platform License (SPL) portfolio, which includes 29 partners supporting 30 clinical and preclinical programs. With a robust balance sheet containing $147.7 million in cash and no debt, a newly authorized $10 million share repurchase program, and a significant reduction in operating expenses following restructuring, MaxCyte is well-positioned for a back-half recovery in 2026 as clinical programs advance toward commercialization. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$2.43 Mean target$4.11 High · most bullish analyst$5.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $2.4015% Core revenue recovery is delayed further due to persistent biotech funding constraints or customer inventory management. Additional SPL program terminations or slower-than-expected clinical progression limit milestone and royalty revenues, keeping the company in a high-burn state. Base CaseCentral scenario $4.5060% MaxCyte achieves its full-year 2026 revenue guidance of $30 million to $32 million, driven by core revenue of $25 million to $27 million and $5 million in SPL milestones and royalties. Operating expenses remain controlled at approximately $60 million, narrowing net losses significantly while maintaining a strong cash cushion above $136 million. Bull CaseUpside scenario $6.0025% Rapid clinical advancement of SPL partners leads to early milestone achievements and higher-than-expected commercial royalties (e.g., from Casgevy). Core instrument sales and processing assembly (PA) recurring revenues rebound strongly in the second half of 2026, exceeding the high end of guidance. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |